ABEO Stock Gains On Approval For A Drug Abeona Sold, Rating For The One It Sells
Abeona stands to collect mid-single-digit royalties on sales of Ultragenyx’s Fayuvi plus up to $30 million in commercial milestone payments as part of a licensing deal. The Food and Drug Administration (FDA) on Thursday approved Ultragenyx’s Fayuvi, the first U.S. treatment for Sanfilippo syndrome type A, a rare and fatal childhood brain disease. Abeona developed … Read more